Valsartan/rosuvastatin - EMS

Drug Profile

Valsartan/rosuvastatin - EMS

Alternative Names: Rosuvastatin/valsartan - EMS

Latest Information Update: 17 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator EMS
  • Class Antihyperlipidaemics; Antihypertensives; Branched-chain amino acids; Fluorobenzenes; Pyrimidines; Small molecules; Sulfonamides; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Dyslipidaemias; Hypertension

Most Recent Events

  • 21 Jan 2016 Clinical trials in Dyslipidaemias in Brazil (PO, Tablet) before January 2016
  • 21 Jan 2016 Clinical trials in Hypertension in Brazil (PO, Tablet) before January 2016
  • 21 Jan 2016 EMS plans a phase III trial for Hypertension and Dyslipidaemias in Brazil (NCT02662894)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top